CRDF
Cardiff Oncology, Inc.NASDAQHealthcare$1.58-1.86%ClosedMarket Cap: $108.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.33
P/S
182.15
EV/EBITDA
-1.96
DCF Value
$0.02
FCF Yield
-35.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
-1890.4%
Operating Margin
-8256.3%
Net Margin
-7732.2%
ROE
-82.0%
ROA
-74.1%
ROIC
-105.9%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $243.0K | 8.2% | $-7.8M | $-7.2M | $-0.11 | — |
| FY 2025 | $593.0K | -52.4% | $-49.0M | $-45.9M | $-0.69 | — |
| Q3 2025 | $120.0K | 100.0% | $-12.0M | $-11.3M | $-0.17 | — |
| Q2 2025 | $121.0K | -9470.2% | $-14.8M | $-13.9M | $-0.21 | — |
| Q1 2025 | $109.0K | 100.0% | $-14.4M | $-13.4M | $-0.28 | — |
| Q4 2024 | $151.0K | 100.0% | $-12.6M | $-11.8M | $-0.25 | — |
| FY 2024 | $683.0K | 100.0% | $-48.7M | $-45.4M | $-0.95 | — |
| Q3 2024 | $165.0K | -5742.4% | $-12.6M | $-11.9M | $-0.25 | — |
| Q2 2024 | $163.0K | 35.6% | $-12.5M | $-11.8M | $-0.26 | — |
| Q1 2024 | $205.0K | 50.2% | $-10.9M | $-10.0M | $-0.22 | — |
| Q4 2023 | $156.0K | 34.0% | $-10.3M | $-9.3M | $-0.21 | — |
| FY 2023 | $488.0K | 100.0% | $-45.4M | $-41.4M | $-0.93 | — |